截至9月30日，瑞迈特股东户数7971.00，较上期增加16.36%；人均流通股7080股，较上期减少14.20%。 2025年1月-9月，瑞迈特实现营业收入8.08亿元，同比增长34.24%；归母净利润1.80亿元，同比增长 43.87%。 分红方面，瑞迈特A股上市后累计派现2.28亿元。 机构持仓方面，截止2025年9月30日，瑞迈特十大流通股东中，汇添富医药保健混合（470006）位居第 六大流通股东，持股129.53万股，为新进股东。 责任编辑：小浪快报 1月26日，瑞迈特跌1.38%，成交额1.36亿元。两融数据显示，当日瑞迈特获融资买入额1975.78万元， 融资偿还1031.42万元，融资净买入944.35万元。截至1月26日，瑞迈特融资融券余额合计1.58亿元。 融资方面，瑞迈特当日融资买入1975.78万元。当前融资余额1.57亿元，占流通市值的2.08%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，瑞迈特1月26日融券偿还100.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量9100.00股，融券余额76.95万元，超过近一年50%分位水平，处于 ...

瑞迈特今年以来股价跌0.86%，近5个交易日跌5.84%，近20日涨2.99%，近60日涨4.62%。 1月23日，瑞迈特盘中上涨2.02%，截至11:17，报84.97元/股，成交6692.39万元，换手率1.14%，总市值 76.13亿元。 分红方面，瑞迈特A股上市后累计派现2.28亿元。 资金流向方面，主力资金净流入488.54万元，大单买入1343.94万元，占比20.08%，卖出855.40万元，占 比12.78%。 机构持仓方面，截止2025年9月30日，瑞迈特十大流通股东中，汇添富医药保健混合（470006）位居第 六大流通股东，持股129.53万股，为新进股东。 资料显示，北京瑞迈特医疗科技股份有限公司位于北京市丰台区丽泽路16号院4号楼北京汇亚大厦17层 10号，成立日期2001年7月27日，上市日期2022年11月1日，公司主营业务涉及研发、生产、销售呼吸健 康领域医疗设备与耗材产品及相关服务,为以阻塞型睡眠呼吸暂停低通气综合征(OSA)为主的睡眠呼吸暂 停低通气综合征(SAHS)患者以及以慢性阻塞性肺疾病(COPD)为主的呼吸功能不全(Respiratory Insufficiency) ...

Core Viewpoint - The stock price of Ruimait has experienced fluctuations, with a recent decline of 2.00% and a total market capitalization of 8.107 billion yuan. The company has seen a net outflow of funds, indicating potential investor caution [1]. Group 1: Stock Performance - Ruimait's stock has increased by 5.57% year-to-date, with a recent decline of 1.16% over the last five trading days. Over the past 20 days, the stock has risen by 6.09%, while it has increased by 3.79% over the last 60 days [2]. - As of January 16, the stock was trading at 90.48 yuan per share, with a trading volume of 50.0166 million yuan and a turnover rate of 0.78% [1]. Group 2: Company Overview - Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector [2]. - The company's main business revenue composition includes home respiratory therapy products (64.19%), consumables (32.67%), medical products (3.05%), and others (0.10%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Ruimait achieved an operating income of 808 million yuan, representing a year-on-year growth of 34.24%. The net profit attributable to shareholders was 180 million yuan, reflecting a year-on-year increase of 43.87% [3]. - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. Group 4: Shareholder Information - As of September 30, 2025, Ruimait had 7,971 shareholders, an increase of 16.36% from the previous period. The average number of circulating shares per person decreased by 14.20% to 7,080 shares [3]. - Among the top ten circulating shareholders, Huatai-PineBridge Healthcare Mixed Fund is the sixth largest, holding 1.2953 million shares as a new shareholder [4].

Group 1 - The core business of the company involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - As of September 30, 2025, the company achieved a revenue of 808 million yuan, representing a year-on-year growth of 34.24%, and a net profit attributable to shareholders of 180 million yuan, with a growth of 43.87% [2] - The company's revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] Group 2 - As of December 31, 2025, the company's financing balance reached 1.30 billion yuan, with a net financing purchase of 136,100 yuan on that day [1] - The company has distributed a total of 228 million yuan in dividends since its A-share listing [3] - The number of shareholders increased by 16.36% to 7,971 as of September 30, 2025, while the average circulating shares per person decreased by 14.20% to 7,080 shares [2]

Core Viewpoint - The stock price of Ruimait has increased by 5.18% on November 21, reaching 97.00 CNY per share, with a total market capitalization of 8.691 billion CNY, reflecting a cumulative increase of 11.11% over the past five days [1] Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The revenue composition of the company includes: 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Ruimait, with the Xinda Small and Medium Cap Mixed A Fund (610004) holding 116,500 shares, accounting for 4.31% of the fund's net value, making it the eighth largest holding [2] - The fund has realized a floating profit of approximately 556,800 CNY today and a total of 1,073,900 CNY during the five-day increase [2] Fund Manager Information - The fund manager of Xinda Small and Medium Cap Mixed A Fund is Zeng Guofu, who has a cumulative tenure of 17 years and 119 days, with a total fund size of 585 million CNY. The best return during his tenure is 109.1%, while the worst is -57.43% [3] - Co-manager Li Diandian has a tenure of 1 year and 38 days, managing a fund size of 525 million CNY, with a best return of 34.07% and a worst return of 12.72% during his tenure [3]

Group 1 - The core viewpoint of the news is that Beijing Ruimait Medical Technology Co., Ltd. has seen a stock price increase of 5.01%, reaching 88.86 CNY per share, with a total market capitalization of 7.962 billion CNY [1] - The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The revenue composition of the company includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - From the perspective of fund holdings, Jin Xin Fund has a significant position in Ruimait, with its Jin Xin Value Selection Mixed A Fund reducing its holdings by 17,000 shares, now holding 15,000 shares, which constitutes 4.2% of the fund's net value [2] - The Jin Xin Value Selection Mixed A Fund has achieved a year-to-date return of 54.11%, ranking 664 out of 8140 in its category [2] - The fund manager Liu Shang has a tenure of 88 days with a total asset scale of 1.09 million CNY, while manager Tan Zhiming has a tenure of 223 days with a total asset scale of 1.41 million CNY [3]

Core Viewpoint - 瑞迈特医疗科技股份有限公司的股价在11月7日上涨5.07%，截至发稿时为90.60元/股，总市值达到81.18亿元 [1] Company Overview - 瑞迈特成立于2001年7月27日，上市于2022年11月1日，主要业务包括研发、生产和销售呼吸健康领域的医疗设备及相关服务 [1] - 公司专注于为阻塞型睡眠呼吸暂停低通气综合征(OSA)和慢性阻塞性肺疾病(COPD)患者提供全周期、多场景的治疗服务 [1] - 主营业务收入构成：家用呼吸诊疗产品占64.19%，耗材占32.67%，医用产品占3.05%，其他占0.10% [1] Shareholder Information - 汇添富医药保健混合基金在瑞迈特的十大流通股东中占据一席，持有129.53万股，占流通股的2.3% [2] - 该基金在三季度新进十大流通股东，今日浮盈约566.03万元 [2] Fund Performance - 汇添富医药保健混合基金的最新规模为24.86亿元，今年以来收益为30.45%，近一年收益为20.86% [2] - 基金经理郑磊的任职时间为10年329天，任职期间最佳基金回报为53.42% [3]

Core Viewpoint - The company 瑞迈特 has experienced fluctuations in its stock price and trading volume, with a notable increase in revenue and net profit year-on-year, indicating strong business performance despite recent market movements [1][3]. Group 1: Stock Performance - As of November 4, 瑞迈特's stock price decreased by 2.03% to 86.07 CNY per share, with a trading volume of 74.94 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 7.71 billion CNY [1]. - Year-to-date, 瑞迈特's stock price has increased by 37.49%, with a 4.23% rise over the last five trading days and a 3.82% increase over the last 20 days, while it has seen a decline of 1.65% over the past 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, 瑞迈特 reported a revenue of 808 million CNY, representing a year-on-year growth of 34.24%, and a net profit attributable to shareholders of 180 million CNY, which is a 43.87% increase compared to the previous year [3]. - The company has distributed a total of 228 million CNY in dividends since its A-share listing [4]. Group 3: Business Overview - 瑞迈特, established on July 27, 2001, and listed on November 1, 2022, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The revenue composition of 瑞迈特 includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as medical devices, small-cap stocks, and financing [2].

Group 1 - The core viewpoint of the news is that Ruimait Medical Technology Co., Ltd. has seen a stock price increase of 5.09%, reaching 89.20 yuan per share, with a total market capitalization of 7.992 billion yuan [1] - Ruimait specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea-hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund's Nord Small and Mid-Cap Mixed Fund holds 18,000 shares of Ruimait, accounting for 5.02% of the fund's net value, making it the fifth-largest holding [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a year-to-date return of 35.43%, ranking 1958 out of 8154 in its category [2] - The fund manager, Zhu Mingrui, has been in position for 3 years and 114 days, with the best fund return during his tenure being 25.82% [3]

Group 1 - The core viewpoint of the news is that Ruimait's stock price has experienced fluctuations, with a recent decline of 2.06% and a year-to-date increase of 36.38% [1][2] - As of October 23, Ruimait's stock price is reported at 85.38 CNY per share, with a market capitalization of 7.65 billion CNY [1] - The company has seen a net outflow of 485,500 CNY in principal funds, with large orders accounting for 18.86% of purchases and 21.33% of sales [1] Group 2 - Ruimait's main business involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] - As of June 30, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3] Group 3 - For the first half of 2025, Ruimait achieved operating revenue of 544 million CNY, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million CNY, also up by 42.19% [3] - Since its A-share listing, Ruimait has distributed a total of 228 million CNY in dividends [4] - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4]